Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

DPP4 in Cardiometabolic Disease
Jixin Zhong, Andrei Maiseyeu, Stephen N. Davis, et al.
Circulation Research (2015) Vol. 116, Iss. 8, pp. 1491-1504
Open Access | Times Cited: 166

Showing 1-25 of 166 citing articles:

COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Soo Lim, Jae Hyun Bae, Hyuk‐Sang Kwon, et al.
Nature Reviews Endocrinology (2020) Vol. 17, Iss. 1, pp. 11-30
Open Access | Times Cited: 929
Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications
Jun Ren, Ne N. Wu, Shuyi Wang, et al.
Physiological Reviews (2021) Vol. 101, Iss. 4, pp. 1745-1807
Open Access | Times Cited: 251
Inter-organ cross-talk in metabolic syndrome
Christina Priest, Peter Tontonoz
Nature Metabolism (2019) Vol. 1, Iss. 12, pp. 1177-1188
Closed Access | Times Cited: 218
Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions
Shiying Shao, Qinqin Xu, Xuefeng Yu, et al.
Pharmacology & Therapeutics (2020) Vol. 209, pp. 107503-107503
Open Access | Times Cited: 174
COVID‐19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
Margaret F. Bassendine, Simon H. Bridge, Geoffrey W. McCaughan, et al.
Journal of Diabetes (2020) Vol. 12, Iss. 9, pp. 649-658
Open Access | Times Cited: 145
Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
Francesco Paneni, Thomas F. Lüscher
The American Journal of Medicine (2017) Vol. 130, Iss. 6, pp. S18-S29
Open Access | Times Cited: 97
DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
Inés Valencia, Concepción Peiró, Óscar Lorenzo, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 95
Structural diversity, functional aspects and future therapeutic applications of human gut microbiome
Soma Ghosh, Sreemanta Pramanik
Archives of Microbiology (2021) Vol. 203, Iss. 9, pp. 5281-5308
Open Access | Times Cited: 90
CD26/dipeptidylpeptidase IV—chemokine interactions: double-edged regulation of inflammation and tumor biology
Anneleen Mortier, Mieke Gouwy, Jo Van Damme, et al.
Journal of Leukocyte Biology (2016) Vol. 99, Iss. 6, pp. 955-969
Open Access | Times Cited: 88
Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19
Vincent J. Venditto, Dalia Haydar, Ahmed Abdel‐Latif, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 58
Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice
Trong Kha Pham, To Nguyen, Joo Mi Yi, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 4, pp. 767-778
Open Access | Times Cited: 31
Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
Francesco Paneni, Thomas F. Lüscher
The American Journal of Cardiology (2017) Vol. 120, Iss. 1, pp. S17-S27
Open Access | Times Cited: 84
Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat–Fed Diabetic Mice
Erin E. Mulvihill, Elodie M. Varin, John R. Ussher, et al.
Diabetes (2015) Vol. 65, Iss. 3, pp. 742-754
Open Access | Times Cited: 81
GLP-1 Agonists and Blood Pressure: A Review of the Evidence
Aditya Goud, Jixin Zhong, Matthew Peters, et al.
Current Hypertension Reports (2016) Vol. 18, Iss. 2
Closed Access | Times Cited: 73
Identification and Quantification of DPP-IV-Inhibitory Peptides from Hydrolyzed-Rapeseed-Protein-Derived Napin with Analysis of the Interactions between Key Residues and Protein Domains
Feiran Xu, Yijun Yao, Xiaoying Xu, et al.
Journal of Agricultural and Food Chemistry (2019) Vol. 67, Iss. 13, pp. 3679-3690
Closed Access | Times Cited: 73
Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease
Jixin Zhong, Sanjay Rajagopalan
Frontiers in Immunology (2015) Vol. 6
Open Access | Times Cited: 72
Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
Jixin Zhong, Quan Gong, Aditya Goud, et al.
Journal of Diabetes Research (2015) Vol. 2015, pp. 1-14
Open Access | Times Cited: 69
Chemokine isoforms and processing in inflammation and immunity
Paul Proost, Sofie Struyf, Jo Van Damme, et al.
Journal of Autoimmunity (2017) Vol. 85, pp. 45-57
Closed Access | Times Cited: 69
Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction
Grazia Esposito, Donato Cappetta, Rosa Russo, et al.
British Journal of Pharmacology (2016) Vol. 174, Iss. 22, pp. 4070-4086
Open Access | Times Cited: 69
Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism
Natasha A. Trzaskalski, Evgenia Fadzeyeva, Erin E. Mulvihill
Clinical Medicine Insights Endocrinology and Diabetes (2020) Vol. 13, pp. 117955142091297-117955142091297
Open Access | Times Cited: 68
Increased dipeptidyl peptidase-4 accelerates diet-related vascular aging and atherosclerosis in ApoE-deficient mice under chronic stress
Yanna Lei, Guang Yang, Lina Hu, et al.
International Journal of Cardiology (2017) Vol. 243, pp. 413-420
Closed Access | Times Cited: 63
Mechanisms and Therapeutic Prospects of Diabetic Cardiomyopathy Through the Inflammatory Response
Namrita Kaur, Yingshu Guan, Rida Raja, et al.
Frontiers in Physiology (2021) Vol. 12
Open Access | Times Cited: 48
Chronic Psychological Stress Accelerates Vascular Senescence and Impairs Ischemia‐Induced Neovascularization: The Role of Dipeptidyl Peptidase‐4/Glucagon‐Like Peptide‐1‐Adiponectin Axis
Limei Piao, Guangxian Zhao, Enbo Zhu, et al.
Journal of the American Heart Association (2017) Vol. 6, Iss. 10
Open Access | Times Cited: 61
Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
Sen Shi, Daisuke Koya, Keizo Kanasaki
Fibrogenesis & Tissue Repair (2016) Vol. 9, Iss. 1
Open Access | Times Cited: 60
Dipeptidyl Peptidase‐4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation
Taichi Ikedo, Manabu Minami, Hiroharu Kataoka, et al.
Journal of the American Heart Association (2017) Vol. 6, Iss. 6
Open Access | Times Cited: 60
Page 1 - Next Page

Scroll to top